Earnings intelligence

Earnings Signals

15s fallback

A clear read on the latest earnings surprise, its evidence, and what could invalidate the call.

JAZZ

Jazz Pharmaceuticals plc

FY2026 · Q3 · reaction revision

Updated
Bullish signal

Long bias

Revenue beat estimates by 2.9%; guidance raised; fresh reaction +8.3%.

Evidence coverage

75%

Completeness,
not win probability

Release
positive
Guidance
raised
Market reaction
+8.31%

EPS

—

Consensus -4.05 USD/share

REVENUE

1,243

Consensus 1,208.245 USDm

Why the model sees it this way

  • EPS: — reported vs -4.05 consensus · consensus comparison incomplete.
  • REVENUE: 1,243 reported vs 1,208.245 consensus · above consensus.
  • Guidance was raised.
  • The measured market reaction was +8.31%.

Risks & open questions

  • Still missing: eps actual and estimate.
  • Still missing: standardized eps surprise.
  • Still missing: reaction spread bps.

Signal track record

Research

Current verdict

The live record is still building

35 directional calls have resolved. That is below the 200-event evidence gate, so results remain preliminary.

Resolved calls

35 / 200

minimum evidence gate

HorizonCallsDirection correctNet meanvs drift95% range
+3 sessions5151.0%-0.17%+0.77%-2.45…1.91%
Evidence history4 revisions

Revision history

  1. Revision 1 · fast release · positive ·
  2. Revision 2 · fast release · positive ·
  3. Revision 3 · fast release · positive ·
  4. Revision 4 · reaction revision · positive ·